Cannabis Law Report

JULY 1, 2021

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression.

Law 59

Law Policy Research and Development Clinical Trials 59

Peninsula Alternative Health

MAY 15, 2019

The joint study conducted by Ben Gurion University and Soroka Medical Center in Beersheba analyzed 188 teens diagnosed with Autistic Spectrum Disorder (ASD) between 2015 and 2017. 2017) The current status of artisanal cannabis for the treatment of epilepsy in the United States. tetrahydrocannabinol (THC). improvement in good sleep.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. In 2017, FDA granted a request for Breakthrough Therapy designation for MDMA to treat PTSD.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. In 2017, the FDA designated MDMA a breakthrough therapy for PTSD.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). That access would be available under the auspices of having a chronic, untreatable mood disorder.

Therapy 89

Therapy Legalization Chronic Pain DEA 89

Peninsula Alternative Health

MAY 15, 2019

The joint study conducted by Ben Gurion University and Soroka Medical Center in Beersheba analyzed 188 teens diagnosed with Autistic Spectrum Disorder (ASD) between 2015 and 2017. 2017) The current status of artisanal cannabis for the treatment of epilepsy in the United States. tetrahydrocannabinol (THC). improvement in good sleep.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

JULY 9, 2021

Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. The review, however, did not cover patient access to medicinal cannabis. Refractory paediatric epilepsy.

Research and Development 52

Research and Development Medicine Access Media 52

TheAnswerPage

JANUARY 11, 2022

For example, most, if not all, states have legalized the use of medical marijuana to treat specific health conditions for which there is no or only poor quality clinical evidence of efficacy and safety. Available at: [link] Accessed 05 Dec. link] -Accessed December 5, 2021. Le-Short C., Narouze S.N. In: Narouze S.N.

Patients 98

Patients Education Marijuana Therapy 98

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). That access would be available under the auspices of having a chronic, untreatable mood disorder.

Legalization 52

Legalization Therapy Chronic Pain DEA 52

The Cannigma

MARCH 12, 2021

At the end of the episode, Debbie Churgai, executive director of Americans for Safe Access, discusses the various ways that military veterans — who could very much benefit from medical cannabis — have difficulty accessing it and the ways that the Veterans Administration can address that issue. Produced by Michael Schaeffer Omer-Man.

Legalization 128

Legalization Patients Education Dispensary 128

Cannabis Law Report

OCTOBER 17, 2019

Many experts believe it can lead to beneficial treatments, reiterated in a report released by the National Academies of Sciences, Engineering, and Medicine in January 2017. Many of these are meant to address public safety risks, especially for young people. Both THC and CBD are psychoactive, but unlike THC, CBD does not intoxicate.

Law 40

Law Seed-To-Sale Hemp Recreational 40

Cannabis Law Report

JUNE 11, 2019

Despite the recent legalization of cannabis, a framework for access to cannabis for medical purposes still exists, but under new regulations passed under the authority of the Cannabis Act. Ahn , 2016 BCSC 795, reversed on other grounds 2017 BCCA 221. Mistry , 2017 BCSC 239. Tower , 2017 BCSC 2068. ” 42.

Chronic Pain 45

Chronic Pain Cannabis History Treatment 45